Description
The Mallinckrodt Institute of Radiology, Washington University in St. Louis has an opening for its one-year fellowship in Nuclear Oncology (Molecular Imaging and Theranostics) for 2026-2027.
The nuclear medicine faculty at Washington University in St Louis includes 15 MD or MD/PhD and 2 PhD members. Nuclear medicine instrumentation includes two clinical PET/CT scanners (including larger axial field of view PET scanner), five SPECT/CT scanners and 7 conventional gamma cameras. We have an onsite Cyclotron Facility and extensive radiochemistry laboratories that provide routine radiopharmaceuticals for clinical use and novel radiopharmaceuticals for research studies. Our Center of Clinical Imaging Research (CCIR) is equipped with two PET/CT and 1 PET/MRI scanners as well as two 3-Telsa MRI scanners. Our Center for Clinical Theranostics Research (CCTR) is equipped with four outpatient radiopharmaceutical therapy bays, dedicated clinical examination rooms, and a hot lab with access to GMP radiopharmaceuticals. We also have inpatient lead shielded rooms for high dose radiopharmaceutical therapy. Dosimetry for radiopharmaceutical therapy is routinely performed in selected patients.
The faculty of the Division of Nuclear medicine are involved in a range of research activities including:
Clinical trials with investigational therapeutic radiopharmaceuticals (neuroendocrine tumors and prostate cancer, as well as other solid tumors, such as neuroblastoma, breast and gastric cancers) and PET/CT with novel radiopharmaceuticals (such as imaging agents targeting progesterone-receptors, PARP, CCR2, VLA-4, PSMA).
Requirements
The applicant should have completed training in Nuclear Medicine and is either ABNM eligible or certified and be interested in participating in research projects. The fellowship, which is not ACGME accredited, will provide extensive oncologic clinical PET/CT, SPECT/CT and nuclear medicine therapy (theranostic) experience. Learning is enhanced through close collaboration with faculty in Radiation Oncology and Medical Oncology. In addition, there will attendance/participation in multidisciplinary tumor boards, as well as lectures, journal clubs and participation in the daily workflow of our imaging and Theranostic Centers. Research opportunities with novel diagnostic and therapeutic radiopharmaceuticals are available.
For more information, or to apply, please contact
Vikas Prasad, M.D., Director of Theranostic Nuclear Medicine
Email: pvikas@wustl.edu
Mallinckrodt Institute of Radiology Website- www.mir.wustl.edu
